masthead-publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Alleles Angiogenesis Anus Apoptosis Autocrine Signaling B-cell lymphoma Biology of neoplasia Biomarker Discovery Biomarker Validation Biomarkers Bladder Bladder Cancer blood Breast Breast Cancer Carcinoma cardiovascular disease CD-19 CDKN2A mutation Cells Checkpoint Inhibitors Circulating miRNAs Clinical Outcome Prediction Coccidioidomycosis Colon Colon cancer Colorectal cancer Comparative Study Cord Blood Buffy Coat Core Needle Biopsy Custom mRNA Cytokines Developmental Immunotherapy Diagnostic Biomarkers Differential Expression Dissecting Genomic Biomarkers DLBCL Drug Response Efficacy EMT Epidemiology outcomes Epstein-Barr Esophageal Cancer Exosomes Extracted RNA Feasibility FFPE FGF Ligand Trap FGFR Gastrointestinal Cancers Gene Expression Comparisons Gene Expression Profiling Gene Expression Signatures Gene Fusions Genetic Polymorphism Head and Neck Cancer Heart HTG EdgeSeq HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Hypoxia Immune Response Immune-checkpoint blockade Immuno-Oncology Immunotherapy Inflammatory Signatures Interferon Gamma Signature Kidney Liposarcoma Liquid Biopsy Liver Lung Lung cancer Lupus Lymphoma Melanoma Mesothelioma Metastatic Colon Cancer Methods Comparison Mice PDX Microenvironment miRNA Molecular Characterization Mouse mRNA mRNA mRNA custom Multiple Myeloma MYC Natural Killer Cells Neoantigens Non-small Cell Lung Cancer Novel Therapeutic Targets NSCLC Oncogenes Oncomirs Oral Cancer Overexpression P13KmTOR Inhibitor Pancreas Pancreatic Cancer Pancreatic Ductal Adenocarcinoma Pancreatic ductal adenocarcinoma Pathology Pathway Analysis Pathways PCA Cell Lines PD-1 Pd-L1 PD-L1 Phase 3 clinical trial PIK3CA mutation Plasma plasma Platform Comparison Predictive Biomarkers Profiling Signature Development Prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 Prostate qNPA qPCR Radiation Toxicities rectum Renal Cell Carcinoma Renal Disease Reveal Rheumatoid Arthritis Rituximab safety Sarcoidosis SCLC Serum Signaling Inhibitors Signaling Pathways Signature Development Signature Validation Sinonasal Undifferentiated Carcinoma Skin Small bowel Small cell bladder cancer Small Cell Bladder Cancer Small Cell Lung Cancer Squamous cell carcinoma Sub-typing System Validation Technology Comparison Therapeutic Response Tissue-based biomarkers TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Triple Negative Breast Cancer Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Mutational Burden tumor mutational burden Type 1 diabetes Urothelial carcinoma Uveal melanoma VEGFR WNT Path Signaling Xenograft Tissue

2020

Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial.

Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)

View External Link

CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.

Lenz, A., et al. CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.  Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)

View External Link

Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session  Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.

View External Link

2019

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)

Martin, M., et al., Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Paper presented at San Antonio Breast Cancer Symposium; 2019 December 10-14; San Antonio, Texas. Session GS2.

Download pdf 1.1MB

Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins

Softic, S., et al. Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins. Cell Metabolism 2019; 30, 735-753.

Download pdf 5.7MB

Molecular Characterization of the Serum Profile Associated to The Increased Cardiovascular Risk in Rheumatoid Arthritis Patients. Effects of Biological Drugs

Perez-Sanches, C., et al. Molecular Characterization of the Serum Profile Associated to The  Increased Cardiovascular Risk in Rheumatoid Arthritis Patients. Effects of Biological Drugs. Annals of the Rheumatic Diseases 2019;78(S2):SAT0124

View External Link

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination

Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629

View External Link

Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.

Battaglin, F., et al. Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2019, Chicago, IL

View External Link

Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).

William, N. W., et al. Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). Presented Clinical Science Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting; June 2, 2019, Chicago, IL. Abstract # 6009

View External Link

Page last updated March 30, 2020